Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

BizVibe Announces Its List of the Best Oncology Pharmaceutical Companies for 2017

Posted on: 30 Aug 17

Oncology drugs are seeing a sharp increase in demand as cancer rates rise worldwide and treatment becomes more advanced and readily available. Competition between oncology pharmaceutical companies is changing in response to consumer needs and market opportunities. Innovation is a major factor in this industry. Key vendors are focusing on the development of multifunctional oncology drugs that offer increased patient comfort, better treatment, and improved patient outcomes for individuals across the world.

This Smart News Release features multimedia. View the full release here:

Best Oncology Pharmaceutical Companies (Graphic: Business Wire)

BizVibe is one of the largest b2b networks for drug manufacturing companies in the world, with over 330,000 buyers, suppliers, and manufacturers in the global pharmaceutical industry.

Network with the Top Oncology Pharmaceutical Companies

In a recent article titled Top 10 Oncology Drugs Companies, BizVibe reveals 2017’s top 10 Oncology pharmacompanies and the best-selling drugs that they are bringing to the market.

Top 10 Oncology Drugs Companies of 2017

10. Bristol-Meyers SquibbBMS has a wide portfolio of oncology drugs. Its top-selling oncology drugs, Erbitux and Yervoy, generated sales totaling USD 1.9 billion and USD 960 million respectively last year.

9. Eli LillyOf Lilly’s total USD 21 billion drug manufacturing revenue from last year, roughly USD 3.72 billion was generated from the company’s oncology segment. Sales of its top-selling oncology drug, Almita, totaled USD 2.5 billion last year.

8. AstraZeneca: Much of AstraZeneca’s revenue is generated through the sale of oncology drugs, including Zoladex, which is used to treat prostate and breast cancers. Sales of Zoladex generate roughly USD 1 billion each year. AstraZeneca generated more than USD 23 billion in revenue last year.

7. AbbVie: In 2015, AbbVie acquired Pharmalytics, an oncology firm, and with it Pharmalytics’s blood cancer treatment,ibrutinib. Global sales of ibrutinib were projected to be worth USD 1 billion in 2016.

6. Celgene: Celgene manufactures Revlimid, one of the best-selling oncology drugs in the world. It treats multiple myeloma. Sales of Revlimid total more than USD 4 billion annually.

Read the Entire Article Here

In addition to top oncology pharma companies, BizVibe is home to more than 7 million companies. Using BizVibe’s platform, users can generate leads, short list prospects, network with businesses from around the world, and trade seamlessly. The BizVibe platform allows you to discover the highest quality leads and make meaningful connections with companies of interest, all in real-time. Claim your company profile for free and let BizVibe connect you with potential business partners. To make things as simple as possible, use the BizVibeChatbot to create new business opportunities.

About BizVibe

The single-minded focus of BizVibe’s platform is to make networking easier. Over the years, we've searched far and wide to figure out how businesses connect and enable trade. That first interaction is usually fraught with the uncertainty of finding a potential partner vs. a potential nightmare. With this in mind, we've designed a robust set of tools to help companies generate leads, short list prospects, network with businesses from around the world and trade seamlessly.

BizVibe is headquartered in Toronto and has offices in London, Bangalore, and Beijing. For more information on the BizVibe network, please contact us.

View source version on

Business Wire

Last updated on: 30/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.